Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07455383 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy sites: 42 to 44Secondary endpoints: details revised at 2 of 9 entries · Eligibility criteria expanded, about 5 wordsShow 2 more changesShow less
Secondary endpoints: details revised at 2 of 9 entries
Eligibility criteria expanded, about 5 words
MinorTrial sites expanded: 29 → 42 locationsv9
MinorTrial sites expanded: 22 → 29 locationsv8
MinorTrial sites expanded: 17 → 22 locationsv7
MinorTrial sites expanded: 9 → 17 locationsv6
MinorStudy Status, Referencesv5
MinorTrial sites expanded: 3 → 9 locationsv4
NotableRecruitment openedTrial sites expanded: 0 → 3 locations · Start date changed from estimate of Mar 2026 to Apr 6, 2026v3Show 2 more changesShow less
Trial sites expanded: 0 → 3 locations
Start date changed from estimate of Mar 2026 to Apr 6, 2026
MinorRe-verified, no change to tracked fieldsv2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.